首页> 美国卫生研究院文献>other >Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration
【2h】

Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration

机译:诱导多能干细胞(iPSC)衍生的视网膜色素上皮(RPE)的致瘤性研究用于治疗年龄相关性黄斑变性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Basic studies of human pluripotential stem cells have advanced rapidly and stem cell products are now seeing therapeutic applications. However, questions remain regarding the tumorigenic potential of such cells. Here, we report the tumorigenic potential of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of wet-type, age-related macular degeneration (AMD). First, immunodeficient mouse strains (nude, SCID, NOD-SCID and NOG) were tested for HeLa cells’ tumor-forming capacity by transplanting various cell doses subcutaneously with or without Matrigel. The 50% Tumor Producing Dose (TPD50 value) is the minimal dose of transplanted cells that generated tumors in 50% of animals. For HeLa cells, the TPD50 was the lowest when cells were embedded in Matrigel and transplanted into NOG mice (TPD50 = 101.1, n = 75). The TPD50 for undifferentiated iPSCs transplanted subcutaneously to NOG mice in Matrigel was 102.12; (n = 30). Based on these experiments, 1×106 iPSC-derived RPE were transplanted subcutaneously with Matrigel, and no tumor was found during 15 months of monitoring (n = 65). Next, to model clinical application, we assessed the tumor-forming potential of HeLa cells and iPSC 201B7 cells following subretinal transplantation of nude rats. The TPD50 for iPSCs was 104.73 (n = 20) and for HeLa cells 101.32 (n = 37) respectively. Next, the tumorigenicity of iPSC-derived RPE was tested in the subretinal space of nude rats by transplanting 0.8–1.5×104 iPSC-derived RPE in a collagen-lined (1 mm×1 mm) sheet. No tumor was found with iPSC-derived RPE sheets during 6–12 months of monitoring (n = 26). Considering the number of rodents used, the monitoring period, the sensitivity of detecting tumors via subcutaneous and subretinal administration routes and the incidence of tumor formation from the iPSC-derived RPE, we conclude that the tumorigenic potential of the iPSC-derived RPE was negligible.
机译:人类多潜能干细胞的基础研究已迅速发展,干细胞产品目前正在治疗中。然而,关于此类细胞的致瘤潜力仍然存在疑问。在这里,我们报告诱导多能干细胞(iPSC)衍生的视网膜色素上皮(RPE)的致瘤潜力,用于治疗湿性,年龄相关性黄斑变性(AMD)。首先,通过在有或没有Matrigel的情况下皮下移植各种剂量的细胞,对免疫缺陷的小鼠品系(裸露,SCID,NOD-SCID和NOG)进行了HeLa细胞肿瘤形成能力的测试。 50%的肿瘤产生剂量(TPD50值)是在50%的动物中产生肿瘤的最小移植剂量。对于HeLa细胞,将细胞包埋在Matrigel中并移植到NOG小鼠中时,TPD50最低(TPD50 = 10 1.1 ,n = 75)。在Matrigel中皮下移植给NOG小鼠的未分化iPSC的TPD50为10 2.12 ; (n = 30)。根据这些实验,将1×10 6 iPSC衍生的RPE与Matrigel皮下移植,在监测的15个月内未发现肿瘤(n = 65)。接下来,为了模拟临床应用,我们评估了裸鼠视网膜下移植后HeLa细胞和iPSC 201B7细胞的肿瘤形成潜力。 iPSC的TPD50为10 4.73 (n = 20),而HeLa细胞的TPD50为10 1.32 (n = 37)。接下来,通过将0.8–1.5×10 4 iPSC衍生的RPE移植到胶原衬里(1 mm×1 mm)的薄片中,在裸鼠的视网膜下间隙中测试iPSC衍生的RPE的致瘤性。 。在监测的6至12个月内,iPSC衍生的RPE床单未发现肿瘤(n = 26)。考虑到使用的啮齿动物数量,监测时间,通过皮下和视网膜下给药途径检测肿瘤的敏感性以及iPSC衍生的RPE形成肿瘤的发生率,我们得出结论,iPSC衍生的RPE的致瘤潜力可忽略不计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号